aTyr Pharma, Inc. is partnering with the Foundation for Sarcoidosis Research (FSR) to recruit for a global pivotal Phase 3 study, EFZO-FIT™, of aTyr’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis. This study comes on...
The Foundation for Sarcoidosis Research (FSR) is pleased to award Dr. Nabeel Hamzeh, Professor of Internal Medicine – Pulmonary, Critical Care and Occupational Medicine at The University of Iowa, funding for cardiac sarcoidosis research in the amount...
“My hope is that this campaign will greatly increase awareness of sarcoidosis and encourage Black patients to participate in clinical trials. That will ultimately improve our lives and benefit everyone in the sarcoidosis community.” Calvin Harris FSR Patient...
If you have sarcoidosis, you MUST join the Foundation for Sarcoidosis Research (FSR) Patient Registry. With less than 200,000 of us diagnosed each year, we are the sources of data needed to advance sarcoidosis research. FSR created the Patient Registry to share...
FSR is proud to announce the launch of the Ignore No More: ACTe Now! (Advance Clinical Trials for Equity in Sarcoidosis) campaign. The goals of this campaign are to increase representation of Black American sarcoidosis patients in clinical trials, raise awareness of...
FSR is pleased to announce that the FSR Sarcoidosis Research Fellowship for 2022-2024 is being awarded to Dr. Nancy Lin from National Jewish Health, a Founding Member of the FSR Global Sarcoidosis Clinic Alliance, for her project, “Defining MicroRNA Biomarkers...
Foundation for Sarcoidosis Research (FSR) announces the launch of the FSR Global Sarcoidosis Clinic Alliance, a groundbreaking initiative that will have a worldwide impact on advancing sarcoidosis research and improving the lives of those with sarcoidosis through...
SUNY Upstate Medical University Auyon Ghosh MD, MPH, to be presented with $50,000 Partnership Research Grant from American Thoracic Society and Foundation for Sarcoidosis Research The Foundation for Sarcoidosis Research (FSR), the leading international nonprofit...
FSR is pleased to announce the 2021 Small Research Grant Awardees. As part of our mission, FSR accelerates sarcoidosis research through fellowships, small grants, and large grant programs, and has dedicated over $5M million for worldwide sarcoidosis research since...
On September 13, 2021, aTyr Pharma announced positive results from their Phase1b/2a clinical trial for ATYR1923 in pulmonary sarcoidosis. FSR is proud to have supported this clinical trial. The trial demonstrated that ATYR1923 was safe and well-tolerated, 33%...
